Nuvectis Pharma, Inc. (NASDAQ: NVCT) has priced its previously announced underwritten public offering of 5 million shares of common stock at $20.00 per share, with expected gross proceeds of approximately $100 million. The company also granted underwriters a 30-day option to purchase up to an additional 750,000 shares at the same price, less underwriting discounts and commissions. The offering is expected to close on or about July 1, 2026, subject to customary closing conditions.
Nuvectis intends to use the net proceeds to advance development of its NXP100, NXP200, and NXP900 programs, support future product candidates, hire additional personnel, fund capital expenditures, and cover general corporate purposes. Cantor is serving as sole book-running manager, with H.C. Wainwright & Co., Laidlaw & Company (UK) Ltd., Lucid Capital Markets, Maxim Group LLC, Roth Capital Partners, and Titan Partners acting as co-managers.
The pricing of this offering is significant for Nuvectis as it provides substantial capital to progress its pipeline, which includes NXP100, a late-stage complement Factor B inhibitor with best-in-class potential for complement-mediated diseases. NXP100 is the only once-daily oral treatment option for these diseases, offering a convenience advantage for patients requiring lifelong therapy. Additionally, NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases, designed to inhibit both catalytic and scaffolding functions of SRC kinase, leading to comprehensive shutdown of the signaling pathway. NXP200 is an oral, brain-penetrant, paradox-breaker BRAF inhibitor targeting BRAF V600X-mutated and Class II/III non-V600-mutated solid tumors, including central nervous system cancer, colorectal cancer, melanoma, and non-small cell lung cancer.
This capital raise underscores the company's commitment to advancing its clinical-stage programs, which address significant unmet needs in immune complement-related conditions and oncology. The funding will enable Nuvectis to potentially bring these innovative therapies closer to patients, impacting treatment paradigms for diseases with limited options. For more information, visit the company's website at https://nuvectis.com/.
